PubMed Central, : RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2011 July; 2(3): e0056. ISSN: 2076-9172Published online 2011 July 31. doi: 10.5041/RMMJ.10056.

Table 2.

Results of the randomized TRITON-TIMI 38 study. At 15 months, the primary efficacy end-point, a combination of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, was reached in favor of prasugrel. The key safety end-point, non-CABG-related TIMI major bleeding, is also listed (in STEMI not significant). For more details, please see text.

	Clopidogrel total (n= 6795)	Prasugrel total (n= 6813)	Clopidogrel STEMI (n= 1765)	Prasugrel STEMI (n= 1769)	Clopidogrel NSTE-ACS (n= 5030)	Prasugrel NSTE-ACS (n= 5044)
Primary end-point	12.1%	9.9%^*	12.4%	10.0%^*	12.1%	9.9%^*
Total mortality	3.2%	3.0%	4.3%	3.3%	2.4%	2.6%
Non-fatal myocardial infarction	9.5%	7.3%^*	9.0%	6.8%^*	9.8%	7.5%^*
Stent thrombosis	2.4%	1.1%^*	2.8	1.6^*	2.2%	1.0%^*
TIMI major bleeding	1.8%	2.4%^*	2.1%	2.4%	1.6%	2.4%^*

^* P < 0.05.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2011 July; 2(3): e0056. ISSN: 2076-9172

Published online 2011 July 31. doi: 10.5041/RMMJ.10056.